In a filing, Axsome Therapeutics Inc revealed its Officer Herriot Tabuteau acquired Company’s shares for reported $7.0 million on Dec 02 ’25. In the deal valued at $142.09 per share,49,252 shares were bought.
Then, Herriot Tabuteau bought 21,775 shares, generating $2,954,650 in total proceeds.
Before that, TABUTEAU HERRIOT sold 91,705 shares. Axsome Therapeutics Inc shares valued at $12,136,240 were divested by the Chief Executive Officer at a price of $132.34 per share. As a result of the transaction, TABUTEAU HERRIOT now holds 7,229 shares, worth roughly $1.03 million.
B. Riley Securities initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on October 01, 2025; the price target was $179. Oppenheimer started covering the stock on June 03, 2025. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -4.66% to $142.09. Over the last five days, the stock has lost -6.03%. Axsome Therapeutics Inc shares have risen nearly 42.59% since the year began. Nevertheless, the stocks have risen 67.94% over the past one year. While a 52-week high of $152.94 was reached on 11/25/25, a 52-week low of $75.56 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 139.44, which if violated will result in even more drops to 136.78. On the upside, there is a resistance level at 147.00. A further resistance level may holdings at 151.90.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-11-14, dropping by 43439.0 shares to a total of 3.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 3.44 million shares. There was a decline of -1.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 07, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $200 price target.
